Flagship pioneering unveils empress therapeutics to revolutionize drug discovery by applying the power of genetics to identify small molecule drugs

Empress's chemilogics™ product platform creates small molecule drugs quickly and cost-effectively the company emerges after two years of platform development with an initial commitment of $50 million from flagship pioneering empress has identified and characterized 15 potential small molecule drugs in less than two years; it expects to file multiple investigational new drug (ind) applications within the next 24 months murray mckinnon, ph.d., former global head of j&j's world without disease accelerator and head of immunology discovery within janssen pharmaceuticals, appointed chief scientific officer cambridge, mass.
FHTX Ratings Summary
FHTX Quant Ranking